CN110996943A - 促肾上腺皮质激素释放因子受体拮抗剂 - Google Patents

促肾上腺皮质激素释放因子受体拮抗剂 Download PDF

Info

Publication number
CN110996943A
CN110996943A CN201880038569.3A CN201880038569A CN110996943A CN 110996943 A CN110996943 A CN 110996943A CN 201880038569 A CN201880038569 A CN 201880038569A CN 110996943 A CN110996943 A CN 110996943A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880038569.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·豪尔顿
H·格伯
M·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spruce Biosciences Inc
Original Assignee
Spruce Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65362494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110996943(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spruce Biosciences Inc filed Critical Spruce Biosciences Inc
Priority to CN202410709847.0A priority Critical patent/CN118845788A/zh
Publication of CN110996943A publication Critical patent/CN110996943A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880038569.3A 2017-08-14 2018-08-14 促肾上腺皮质激素释放因子受体拮抗剂 Pending CN110996943A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410709847.0A CN118845788A (zh) 2017-08-14 2018-08-14 促肾上腺皮质激素释放因子受体拮抗剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545406P 2017-08-14 2017-08-14
US62/545,406 2017-08-14
PCT/US2018/046760 WO2019036503A1 (en) 2017-08-14 2018-08-14 CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410709847.0A Division CN118845788A (zh) 2017-08-14 2018-08-14 促肾上腺皮质激素释放因子受体拮抗剂

Publications (1)

Publication Number Publication Date
CN110996943A true CN110996943A (zh) 2020-04-10

Family

ID=65362494

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410709847.0A Pending CN118845788A (zh) 2017-08-14 2018-08-14 促肾上腺皮质激素释放因子受体拮抗剂
CN201880038569.3A Pending CN110996943A (zh) 2017-08-14 2018-08-14 促肾上腺皮质激素释放因子受体拮抗剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410709847.0A Pending CN118845788A (zh) 2017-08-14 2018-08-14 促肾上腺皮质激素释放因子受体拮抗剂

Country Status (11)

Country Link
US (9) US20210361664A1 (enExample)
EP (1) EP3628005A4 (enExample)
JP (3) JP7398963B2 (enExample)
KR (2) KR20200040761A (enExample)
CN (2) CN118845788A (enExample)
AU (2) AU2018317398A1 (enExample)
BR (1) BR112020002967A2 (enExample)
CA (1) CA3064464A1 (enExample)
EA (1) EA202090450A1 (enExample)
MX (2) MX2019015320A (enExample)
WO (1) WO2019036503A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102740A (zh) 2014-01-21 2016-11-09 纽罗克里生物科学有限公司 治疗先天性肾上腺增生的crf1受体拮抗剂
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP3784233B1 (en) 2018-04-27 2024-06-05 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
EP3984523B1 (en) 2018-12-07 2025-09-03 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) * 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
WO2021062246A1 (en) 2019-09-27 2021-04-01 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
EP4175572A4 (en) * 2020-08-12 2024-03-27 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2022046905A1 (en) * 2020-08-26 2022-03-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516887A (zh) * 2006-09-20 2009-08-26 伊莱利利公司 作为crf1受体拮抗剂的噻唑吡唑并嘧啶类
WO2015112642A1 (en) * 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2128544T3 (es) 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
PL191271B1 (pl) 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
ES2294800T3 (es) 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
PL195762B1 (pl) 1996-07-24 2007-10-31 Bristol Myers Squibb Pharma Co Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
IL137019A0 (en) 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
IL137019A (en) 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
ATE347553T1 (de) 1999-09-30 2006-12-15 Neurogen Corp Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
BR0008059A (pt) 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
DE60218434T2 (de) 2001-03-13 2007-11-08 Bristol-Myers Squibb Pharma Co. 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
WO2005020910A2 (en) 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
EP2272514A1 (en) 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
RU2394035C2 (ru) 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним
US20070129382A1 (en) 2004-02-13 2007-06-07 Dimitri Grigoriadis Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses
WO2005079807A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
DK1869049T3 (da) 2005-03-21 2009-05-18 Lilly Co Eli Imidazopyridazinforbindelser
CN101516835A (zh) 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
ES2428543T3 (es) 2006-09-20 2013-11-08 Eli Lilly And Company Compuestos de tiofenopirazolopirimidina
US8952207B2 (en) 2007-09-11 2015-02-10 The University Of Houston System Copper-catalyzed C—H bond arylation
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
MX2011003529A (es) 2008-10-02 2011-04-21 Lilly Co Eli Compuestos de tiazolil-pirazolopirimidina como intermediarios sinteticos y procesos sinteticos relacionados.
EP3486648B1 (en) * 2008-12-24 2025-04-30 Quest Diagnostics Investments Incorporated Mass spectrometry assay for congenital adrenal hyperplasia
EP2682111A1 (en) * 2009-12-31 2014-01-08 Differential Drug Development Associates LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
WO2013134548A2 (en) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
JP2015516979A (ja) 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
US11045244B2 (en) 2015-03-31 2021-06-29 AblaCare, Inc. Methods and systems for the manipulation of ovarian tissues
CA3064445A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP3784233B1 (en) 2018-04-27 2024-06-05 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
EP3984523B1 (en) 2018-12-07 2025-09-03 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US20200255436A1 (en) 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
JP2022541550A (ja) 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
EP4175572A4 (en) 2020-08-12 2024-03-27 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
KR20240109274A (ko) 2021-11-19 2024-07-10 스프루스 바이오사이언시스 인코포레이티드 틸다서폰트의 결정질 조성물 및 이의 사용 및 제조 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516887A (zh) * 2006-09-20 2009-08-26 伊莱利利公司 作为crf1受体拮抗剂的噻唑吡唑并嘧啶类
WO2015112642A1 (en) * 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADINA F. TURCU等: "Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency", 《J CLIN ENDOCRINOL METAB》 *

Also Published As

Publication number Publication date
US20230414627A1 (en) 2023-12-28
KR20200040761A (ko) 2020-04-20
US11351177B2 (en) 2022-06-07
WO2019036503A1 (en) 2019-02-21
KR20250022913A (ko) 2025-02-17
US11344557B2 (en) 2022-05-31
US12115166B2 (en) 2024-10-15
US20220143037A1 (en) 2022-05-12
JP7398963B2 (ja) 2023-12-15
US20230321112A1 (en) 2023-10-12
US11007201B2 (en) 2021-05-18
JP2024001014A (ja) 2024-01-09
US20190262349A1 (en) 2019-08-29
JP2020530831A (ja) 2020-10-29
US10849908B2 (en) 2020-12-01
EA202090450A1 (ru) 2020-09-24
JP7573080B2 (ja) 2024-10-24
CN118845788A (zh) 2024-10-29
US20210015827A1 (en) 2021-01-21
US20210038609A1 (en) 2021-02-11
BR112020002967A2 (pt) 2020-08-11
MX2023000501A (es) 2023-02-13
EP3628005A4 (en) 2021-01-20
AU2018317398A1 (en) 2019-11-21
US20210361664A1 (en) 2021-11-25
MX2019015320A (es) 2020-07-20
AU2023200189A1 (en) 2023-02-16
EP3628005A1 (en) 2020-04-01
US11311549B2 (en) 2022-04-26
US20210322431A1 (en) 2021-10-21
AU2023200189B2 (en) 2024-02-22
US20210322430A1 (en) 2021-10-21
JP2025020148A (ja) 2025-02-12
CA3064464A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
JP7720354B2 (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP7573080B2 (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
WO2021016208A1 (en) Methods of treating congenital adrenal hyperplasia
US20200255436A1 (en) Corticotropin releasing factor receptor antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410